In one of the few published cases of PSMA-based targeted radionuclide therapy in breast cancer, Tolkach et al. shares their experience in treating a young woman with an aggressive triple negative breast cancer that was unresponsive to several conventional lines of therapy. The gene discussed is FOLH1; the disease is triple-negative breast carcinoma.